Colorectal cancer

There are 1.4 million people in the US with a history of colorectal cancer (CRC). Although the mortality rate has declined in recent decades, incidence rates are expected to rise due to the aging population and increasing occurrence of CRC in younger individuals. Cancerous or precancerous cells in the colon form lesions which are typically detected via colonoscopy, but the technique is invasive, expensive, and only 39% of patients return for subsequent screening. There is a need for improved non-invasive screening methods. We are using an innovative source to detect CRC: the human microbiome. Human microbiome can directly contribute to the development of CRC. We try to identify microbial biomarkers associated with CRC and to develop computational models that improve the non-invasive detection of CRC.

  1. Topcuoglu BD, Lesniak NA, Ruffin MT IV, Wiens J, Schloss PD. 2020. Effective application of machine learning to microbiome-based classification problems. mBio. 11: 1-13. DOI: 10.1128/mBio.00434-20.
  2. Yu AI, Zhao L, Eaton KA, Ho S, Chen J, Poe S, Becker J, Gonzalez A, McKinstry D, Hasso M, Mendoza-Castrejon J, Whitfield J, Koumpouras C, Schloss PD, Martens EC, and Chen GY. 2020. Gut microbiota modulate CD8 T cell responses to influence colitis-associated tumorigenesis. Cell Reports. 31: 107471. DOI: 10.1016/j.celrep.2020.03.035.
  3. Sze MA, Topcuoglu BD, Lesniak NA, IV Ruffin MT, Schloss PD. 2019. Fecal short-chain fatty acids are not predictive of colonic tumor status and cannot be predicted based on bacterial community structure. mBio. 10: e01454-19. DOI: 10.1128/mBio.01454-19.
  4. Flynn KJ, Ruffin MT IV, Turgeon DK, Schloss PD. 2018. Spatial variation of the native colon microbiota in healthy adults. Cancer Prev Res (Phila). 11: 393-401. DOI: 10.1158/1940-6207.CAPR-17-0370.
  5. Hannigan GD, Duhaime MB, Ruffin IV MT, Koumpouras CC, Schloss PD. 2018. The Diagnostic Potential and Interactive Dynamics of the Colorectal Cancer Virome. mBio. 9: e02248-18. DOI: 10.1128/mBio.02248-18.

See more…

Clostridium difficile Infection

Clostridium difficile infection (CDI) following therapeutic antibiotic treatment represents a considerable threat to human health, each year causing as many as half a million infections, 29,000 deaths, and a healthcare burden of $4.8 million. CDI can cause severe abdominal pain and diarrhea, and can develop the life-threatening conditions, which it accomplishes through secretion of protein toxins. Infections in healthy individuals are uncommon, as the combination of the innate immune system and gut microbiome prevent colonization under ordinary circumstances. However, disruption of the native gut bacterial communities during antibiotic therapy, often for unrelated illness, provides opportunity for C. difficile to establish infection. Subsequent treatment of CDI with antibiotics is typically effective, but recurrence of disease is common and may be increasing in prevalence. This, in combination with increased prevalence of infection, the emergence of more virulent forms of the pathogen, and the ever-present threat of antibiotic resistance highlight the need to better understand the mechanisms by which the gut immune system and the resident microbiota prevent initial colonization and subsequent recurrence by C. difficile. We use a combination of 16S rRNA gene sequencing, metagenomics, metatranscriptomics, and metabolomics in a mouse model for CDI and in infected patients to identify microbial functions that are important for colonization resistance and clearance of C. difficile.

  1. Stough JMA, Beaudoin AJ, Schloss PD. 2020. Coding-complete RNA virus genomes assembled from murine cecal metatranscriptomes. Microbiology Resource Announcements. 9: e00018-20. DOI: 10.1128/MRA.00018-20.
  2. Maseda D, Zackular JP, Trindade B, Kirk L, Lising Roxas J, Rogers LM, Washington MK, Du L, Koyama T, Viswanathan VK, Vedantam G, Schloss PD, Crofford LJ, Skaar EP, Aronoff DM. 2019. Nonsteroidal anti-inflammatory drugs alter the microbiota and exacerbate Clostridium difficile colitis while dysregulating the inflammatory response. mBio. 10: e02282-18. DOI: 10.1128/mBio.02282-18.
  3. Tomkovich S, Lesniak NA, Li Y, Bishop L, Fitzgerald MG, Schloss PD. 2019. The proton pump inhibitor omeprazole does not promote Clostridium difficile colonization in a murine model. mSphere. 4: e00693-19. DOI: 10.1128/mSphere.00693-19.
  4. Jenior ML, Leslie JL, Young VB, Schloss PD. 2018. Clostridium difficile differentially alters the structure and metabolism of distinct cecal microbiomes to promote persistent colonization during infection. mSphere. 3: e00261-18. DOI: 10.1128/mSphere.00261-18.
  5. Jenior ML, Leslie JL, Young VB, Schloss PD. 2017. Clostridium difficile colonizes alternative nutrient niches during infection across distinct murine gut environments. mSystems. 2: e00063-17. DOI: 10.1128/mSystems.00063-17.

See more…

Bioinformatic tool development

The ability to generate data that describes the microbial world continues to grow rapidly. This requires that we develop and assess computational tools that allow us to synthesize these data to tell robust and compelling stories that solve important problems. We have been at the fore front of efforts to develop tools that are widely used by microbial ecologists for the past 15 years. Our tools have facilitated the analysis of 16S rRNA gene, metagenomic, and metatranscriptomic sequence data, metabolomics data, and clinical data.

  1. Puckett SP, Samples RM, Schloss PD, and Balunas MJ. 2020. Metabolomics of the microbiome: Characterizing molecular diversity in complex microbial systems, p. 1-17. In Begley TP and Liu H-W (ed.), Comprehensive Natural Products III: Chemistry and Biology. Elsevier. DOI: 10.1016/B978-0-12-409547-2.14802-4.
  2. Schloss PD. 2020. Reintroducing mothur: 10 years later. Applied and Environmental Microbiology. 86: e02343-19. DOI: 10.1128/AEM.02343-19.
  3. Schloss PD. 2018. The Riffomonas Reproducible Research Tutorial Series. The Journal of Open Source Education. 1: 13. DOI: 10.21105/jose.00013.
  4. Westcott SL, Schloss PD. 2017. OptiClust, an Improved Method for Assigning Amplicon-Based Sequence Data to Operational Taxonomic Units. mSphere. 2: e00073-17. DOI: 10.1128/mSphereDirect.00073-17.
  5. Schloss PD, Jenior ML, Koumpouras CC, Westcott SL, Highlander SK. 2016. Sequencing 16S rRNA gene fragments using the PacBio SMRT DNA sequencing system. PeerJ. 4: e1869. DOI: 10.7717/peerj.1869.

See more…

General microbiome research

We take an expansive approach to defining microbiomes. If it’s a community of microorganisms - bacteria, archaea, microeukaryotes, viruses - and it interacts with a biotic or abiotic environment, then it’s a microbiome. Although most of our ongoing work focuses on microbiomes associated with human or murine hosts, we have also studied microbiomes in hydrothermal vents, insects, sand dunes, soil, and more! We have also developed laboratory approaches to improve our ability to study these microbiomes.

  1. Baxter NT, Lesniak NA, Sinani H, Schloss PD, Koropatkin NM. 2019. The glucoamylase inhibitor acarbose has a diet-dependent and reversible effect on the murine gut microbiome. mSphere. 4: e00528-18. DOI: 10.1128/mSphere.00528-18.
  2. Sze MA, Schloss PD. 2019. The impact of DNA polymerase and number of rounds of amplification in PCR on 16S rRNA gene sequence data. mSphere. 4: e00163-19. DOI: 10.1128/mSphere.00163-19.
  3. Doherty MD, Ding T, Koumpouras C, Telesco SE, Monast C, Das A, Brodmerkel C, Schloss PD. 2018. Fecal microbiota signatures are associated with response to Ustekinumab therapy among Crohn’s Disease patients. mBio. 9: e02120-17. DOI: 10.1128/mBio.02120-17.
  4. Hannigan GD, Duhaime MB, Koutra D, Schloss PD. 2018. Biogeography & environmental conditions shape bacteriophage-bacteria networks across the human microbiome. PLOS Comp Biol. 14: e1006099. DOI: 10.1371/journal.pcbi.1006099.
  5. Majid SA, Graw MF, Chatziefthimiou AD, Nguyen H, Richer R, Louge M, Sultan AA, Schloss P, Hay AG. 2016. Microbial Characterization of Qatari Barchan Sand Dunes. PLOS ONE. 11: e0161836. DOI: 10.1371/journal.pone.0161836.

See more…

Scientific culture

How we do science and who does it is as important as what we are sciencing. Our research group has been very interested in reproducibility, publishing, and open access. We try to lead by example without drawing much attention to how we are doing it. Sometimes, it’s important to be more vocal about what we think is important.

  1. Schloss PD, Junior M, Alvania R, Arias CA, Baumler A, Casadevall A, Detweiler C, Drake H, Gilbert J, Imperiale MJ, Lovett S, Maloy S, McAdam AJ, Newton ILG, Sadowsky MJ, Sandri-Goldin RM, Silhavy TJ, Tontonoz P, Young J-AH, Cameron CE, Cann I, Fuller AO, Kozik AJ. 2020. The ASM Journals Committee values the contributions of Black microbiologists. mBio. 11: e01998-20 (simultaneously published in all ASM journals). DOI: 10.1128/mBio.01998-20.
  2. Amann RI, Baichoo S, Blencowe BJ, Bork P, Borodovsky M, Brooksbank C, Chain PSG, Colwell RR, Daffonchio DG, Danchin A, de Lorenzo V, Dorrestein PC, Finn RD, Fraser CM, Gilbert JA, Hallam SJ, Hugenholtz P, Ioannidis JPA, Jansson JK, Kim JF, Klenk HP, Klotz MG, Knight R, Konstantinidis KT, Kyrpides NC, Mason CE, McHardy AC, Meyer F, Ouzounis CA, Patrinos AAN, Podar M, Pollard KS, Ravel J, Muñoz AR, Roberts RJ, Rosselló-Móra R, Sansone SA, Schloss PD, Schriml LM, Setubal JC, Sorek R, Stevens RL, Tiedje JM, Turjanski A, Tyson GW, Ussery DW, Weinstock GM, White O, Whitman WB, Xenarios I. 2019. Toward unrestricted use of public genomic data. Science. 363: 350-352. DOI: 10.1126/science.aaw1280.
  3. Casadevall A, Schloss PD. 2019. Explaining order among those who share positions in the author byline. mBio. 10: e01981-19. DOI: 10.1128/mBio.01981-19.
  4. Schloss PD. 2018. In Defense of an Academic Career in Microbiology. mSphere. 3: e00575-17. DOI: 10.1128/mSphere.00575-17.
  5. Schloss PD. 2018. Jo Handelsman: Adviser, teacher, role model, friend, p. 159-169. In Whitaker RJ & Barton HA (ed.), Women in Microbiology. ASM Press, Washington DC. DOI: 10.1128/9781555819545.ch18.

See more…